<?xml version="1.0" encoding="utf-8"?><xml><records><record><contributors><authors><author><style face="normal" font="default" size="100%">Pavan, C</style></author><author><style face="normal" font="default" size="100%">Davidson, KC</style></author><author><style face="normal" font="default" size="100%">Payne, N</style></author><author><style face="normal" font="default" size="100%">Frausin, S</style></author><author><style face="normal" font="default" size="100%">Hunt, CPJ</style></author><author><style face="normal" font="default" size="100%">Moriarty, N</style></author><author><style face="normal" font="default" size="100%">Berrocal Rubio, MÁ</style></author><author><style face="normal" font="default" size="100%">Elahi, Z</style></author><author><style face="normal" font="default" size="100%">Quattrocchi, AT</style></author><author><style face="normal" font="default" size="100%">Abu-Bonsrah, KD</style></author><author><style face="normal" font="default" size="100%">Wang, L</style></author><author><style face="normal" font="default" size="100%">Clow, W</style></author><author><style face="normal" font="default" size="100%">Yang, H</style></author><author><style face="normal" font="default" size="100%">Pellegrini, M</style></author><author><style face="normal" font="default" size="100%">Wells, CA</style></author><author><style face="normal" font="default" size="100%">Thompson, LH</style></author><author><style face="normal" font="default" size="100%">Nagy, A</style></author><author><style face="normal" font="default" size="100%">Parish, CL</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A cloaked human stem-cell-derived neural graft capable of functional integration and immune evasion in rodent models</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Stem Cell</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell Stem Cell</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cell Press</style></full-title><abbr-1><style face="normal" font="default" size="100%">Cell Press</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">710-726.e8</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">*Immune Evasion</style></keyword><keyword><style face="normal" font="default" size="100%">*Pluripotent Stem Cells/cytology</style></keyword><keyword><style face="normal" font="default" size="100%">*Neurons/cytology/transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">*Neural Stem Cells/transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Coculture Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">*Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson’s disease</style></keyword><keyword><style face="normal" font="default" size="100%">allografting</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine</style></keyword><keyword><style face="normal" font="default" size="100%">graft integration</style></keyword><keyword><style face="normal" font="default" size="100%">graft rejection</style></keyword><keyword><style face="normal" font="default" size="100%">human pluripotent stem cells</style></keyword><keyword><style face="normal" font="default" size="100%">immune evasion</style></keyword><keyword><style face="normal" font="default" size="100%">suicide gene</style></keyword><keyword><style face="normal" font="default" size="100%">transplantation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 1</style></date></pub-dates></dates><abstract><style face="normal" font="default" size="100%">Human pluripotent stem cell (hPSC)-derived therapies are a realistic possibility for numerous disorders, including Parkinson's disease. While generating replacement neurons is achievable, immunosuppressive drug challenges, to prevent rejection, remain. Here we adopted a hPSC line (termed H1-FS-8IM), engineered to overexpress 8 immunomodulatory transgenes, to enable transplant immune evasion. In co-cultures, H1-FS-8IM PSC-derived midbrain neurons evaded rejection by T lymphocytes, natural killer cells, macrophages, and dendritic cells. In humanized mice, allogeneic H1-FS-8IM neural grafts evaded rejection, while control hPSC-derived neural grafts evoked activation of human immune cells, elevated inflammatory cytokines in blood and cerebrospinal fluid, and caused spleen and lymph node enlargement. H1-FS-8IM neural grafts retained functionality, reversing motor deficits in Parkinsonian rats. Additional incorporation of a suicide gene into the H1-FS-8IM hPSC line enabled proliferative cell elimination within grafts. Findings demonstrate feasibility of generating a population-wide applicable, safe, off-the-shelf cell product, suitable for treating diseases for which cell-based therapies are a viable option.</style></abstract><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.stem.2025.03.008</style></electronic-resource-num></record><record><contributors><authors><author><style face="normal" font="default" size="100%">Lahouel, K</style></author><author><style face="normal" font="default" size="100%">Douville, C</style></author><author><style face="normal" font="default" size="100%">Diergaarde, B</style></author><author><style face="normal" font="default" size="100%">Cohen, JD</style></author><author><style face="normal" font="default" size="100%">Grant, H</style></author><author><style face="normal" font="default" size="100%">Kuo, A</style></author><author><style face="normal" font="default" size="100%">Ansari, SK</style></author><author><style face="normal" font="default" size="100%">Wang, Y</style></author><author><style face="normal" font="default" size="100%">O'Broin-Lennon, AM</style></author><author><style face="normal" font="default" size="100%">Popoli, M</style></author><author><style face="normal" font="default" size="100%">Ptak, J</style></author><author><style face="normal" font="default" size="100%">Silliman, N</style></author><author><style face="normal" font="default" size="100%">Dobbyn, L</style></author><author><style face="normal" font="default" size="100%">Nehme, N</style></author><author><style face="normal" font="default" size="100%">Tie, J</style></author><author><style face="normal" font="default" size="100%">Gibbs, P</style></author><author><style face="normal" font="default" size="100%">Papadopoulos, N</style></author><author><style face="normal" font="default" size="100%">Kinzler, KW</style></author><author><style face="normal" font="default" size="100%">Vogelstein, B</style></author><author><style face="normal" font="default" size="100%">Schoen, RE</style></author><author><style face="normal" font="default" size="100%">Tomasetti, C</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Blood-based Assay for Detection of Patients with Advanced Adenomas</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Research Communications</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cancer Research Communications</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">AACR</style></full-title><abbr-1><style face="normal" font="default" size="100%">AACR</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">621-631</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Adenoma/blood/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Early Detection of Cancer/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Colorectal Neoplasms/blood/diagnosis/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Biomarkers, Tumor/blood</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell-Free Nucleic Acids/blood</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Aneuploidy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 18</style></date></pub-dates></dates><abstract><style face="normal" font="default" size="100%">Screening for colorectal cancer (CRC) with blood-based testing should detect advanced adenomas (AAs), facilitating more effective cancer prevention. We evaluated four different methods to detect AAs in plasma: (a) a machine-learning algorithm, SignaL (Signatures of fragment Length), based on cell-free DNA (cfDNA) fragmentation; (b) a "Protein-17" assay measuring 17 cancer-associated proteins; (c) a Global Aneuploidy Score (GAS); and (d) cfDNA mutation analysis querying 15 genes commonly mutated in CRC. Existing data from study populations with and without cancer were utilized to determine 99.5% specificity thresholds. We studied 40 AA cases and 32 colonoscopy-negative controls. SignaL detected 9/40 AAs (22.5%, 95%CI: 12.3-37.5%) at 100% specificity (95%CI: 89.3-100%). Protein-17 detected 5/40 AAs (12.5%, 95%CI: 5.5-26.1%) including three cases not identified by SignaL, at 100% specificity (95%CI: 89.3 to 100%). GAS detected 11/40 AAs (27.5%, 95%CI: 16.1-42.8%), but resulted in 2/32 positive controls (93.8% specificity, 95%CI: 79.9-98.3%). Combining SignaL, the Protein-17 assay, and GAS at the 99.5% specificity thresholds resulted in detection of 16/40 AAs (40%, 95% CI:26.3-55.4%) at 93.8% specificity (95% CI: 79.9% to 98.3%). Of 32/40 evaluable AA plasma samples, only one was cfDNA mutation positive at 0.01 level of significance. A blood-based assay based on the analysis of repeated sequence elements plus proteins appears to be able to detect a considerable fraction of patients with AA at relatively high specificity. Large, prospective studies are required to determine whether this approach can add to the options currently available for screening patients for pre-malignant lesions of the colon.</style></abstract><electronic-resource-num><style face="normal" font="default" size="100%">10.1158/2767-9764.Crc-24-0398</style></electronic-resource-num></record><record><contributors><authors><author><style face="normal" font="default" size="100%">Hotchkiss, KM</style></author><author><style face="normal" font="default" size="100%">Karschnia, P</style></author><author><style face="normal" font="default" size="100%">Schreck, KC</style></author><author><style face="normal" font="default" size="100%">Geurts, M</style></author><author><style face="normal" font="default" size="100%">Cloughesy, TF</style></author><author><style face="normal" font="default" size="100%">Huse, J</style></author><author><style face="normal" font="default" size="100%">Duke, ES</style></author><author><style face="normal" font="default" size="100%">Lathia, J</style></author><author><style face="normal" font="default" size="100%">Ashley, DM</style></author><author><style face="normal" font="default" size="100%">Nduom, EK</style></author><author><style face="normal" font="default" size="100%">Long, G</style></author><author><style face="normal" font="default" size="100%">Singh, K</style></author><author><style face="normal" font="default" size="100%">Chalmers, A</style></author><author><style face="normal" font="default" size="100%">Ahluwalia, MS</style></author><author><style face="normal" font="default" size="100%">Heimberger, A</style></author><author><style face="normal" font="default" size="100%">Bagley, S</style></author><author><style face="normal" font="default" size="100%">Todo, T</style></author><author><style face="normal" font="default" size="100%">Verhaak, R</style></author><author><style face="normal" font="default" size="100%">Kelly, PD</style></author><author><style face="normal" font="default" size="100%">Hervey-Jumper, S</style></author><author><style face="normal" font="default" size="100%">de Groot, J</style></author><author><style face="normal" font="default" size="100%">Patel, A</style></author><author><style face="normal" font="default" size="100%">Fecci, P</style></author><author><style face="normal" font="default" size="100%">Parney, I</style></author><author><style face="normal" font="default" size="100%">Wykes, V</style></author><author><style face="normal" font="default" size="100%">Watts, C</style></author><author><style face="normal" font="default" size="100%">Burns, TC</style></author><author><style face="normal" font="default" size="100%">Sanai, N</style></author><author><style face="normal" font="default" size="100%">Preusser, M</style></author><author><style face="normal" font="default" size="100%">Tonn, JC</style></author><author><style face="normal" font="default" size="100%">Drummond, KJ</style></author><author><style face="normal" font="default" size="100%">Platten, M</style></author><author><style face="normal" font="default" size="100%">Das, S</style></author><author><style face="normal" font="default" size="100%">Tanner, K</style></author><author><style face="normal" font="default" size="100%">Vogelbaum, MA</style></author><author><style face="normal" font="default" size="100%">Weller, M</style></author><author><style face="normal" font="default" size="100%">Whittle, JR</style></author><author><style face="normal" font="default" size="100%">Berger, MS</style></author><author><style face="normal" font="default" size="100%">Khasraw, M</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A brave new framework for glioma drug development</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Oncology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Lancet Oncology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Elsevier</style></full-title><abbr-1><style face="normal" font="default" size="100%">Elsevier</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">e512-e519</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Brain Neoplasms/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioma/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Drug Development</style></keyword><keyword><style face="normal" font="default" size="100%">Antineoplastic Agents/therapeutic use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><abstract><style face="normal" font="default" size="100%">Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.</style></abstract><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/s1470-2045(24)00190-6</style></electronic-resource-num></record><record><contributors><authors><author><style face="normal" font="default" size="100%">Li, J</style></author><author><style face="normal" font="default" size="100%">Mui, JW</style></author><author><style face="normal" font="default" size="100%">da Silva, BM</style></author><author><style face="normal" font="default" size="100%">Pires, DEV</style></author><author><style face="normal" font="default" size="100%">Ascher, DB</style></author><author><style face="normal" font="default" size="100%">Madiedo Soler, N</style></author><author><style face="normal" font="default" size="100%">Goddard-Borger, ED</style></author><author><style face="normal" font="default" size="100%">Williams, SJ</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Broad-Spectrum alpha-Glucosidase of Glycoside Hydrolase Family 13 from Marinovum sp., a Member of the Roseobacter Clade</style></title><secondary-title><style face="normal" font="default" size="100%">Applied Biochemistry and Biotechnology</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Applied Biochemistry and Biotechnology</style></alt-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Springer</style></full-title><abbr-1><style face="normal" font="default" size="100%">Springer</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">6059-6071</style></pages><volume><style face="normal" font="default" size="100%">196</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">*alpha-Glucosidases/genetics/chemistry/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Roseobacter/enzymology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Substrate Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Multigene Family</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial Proteins/genetics/chemistry/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Models, Molecular</style></keyword><keyword><style face="normal" font="default" size="100%">Bioinformatics</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrates</style></keyword><keyword><style face="normal" font="default" size="100%">Enzymes</style></keyword><keyword><style face="normal" font="default" size="100%">Glycosidase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sept</style></date></pub-dates></dates><abstract><style face="normal" font="default" size="100%">Glycoside hydrolases (GHs) are a diverse group of enzymes that catalyze the hydrolysis of glycosidic bonds. The Carbohydrate-Active enZymes (CAZy) classification organizes GHs into families based on sequence data and function, with fewer than 1% of the predicted proteins characterized biochemically. Consideration of genomic context can provide clues to infer possible enzyme activities for proteins of unknown function. We used the MultiGeneBLAST tool to discover a gene cluster in Marinovum sp., a member of the marine Roseobacter clade, that encodes homologues of enzymes belonging to the sulfoquinovose monooxygenase pathway for sulfosugar catabolism. This cluster lacks a gene encoding a classical family GH31 sulfoquinovosidase candidate, but which instead includes an uncharacterized family GH13 protein (MsGH13) that we hypothesized could be a non-classical sulfoquinovosidase. Surprisingly, recombinant MsGH13 lacks sulfoquinovosidase activity and is a broad-spectrum alpha-glucosidase that is active on a diverse array of alpha-linked disaccharides, including maltose, sucrose, nigerose, trehalose, isomaltose, and kojibiose. Using AlphaFold, a 3D model for the MsGH13 enzyme was constructed that predicted its active site shared close similarity with an alpha-glucosidase from Halomonas sp. H11 of the same GH13 subfamily that shows narrower substrate specificity.</style></abstract><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12010-023-04820-3</style></electronic-resource-num></record></records></xml>